Page last updated: 2024-10-19

nitrites and Heart Failure

nitrites has been researched along with Heart Failure in 71 studies

Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)

Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to evaluate the hemodynamic effect of L-arginine infusion in patients with congestive heart failure."9.08Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. ( Blum, M; Bogomolny, N; Chernichowsky, T; Finkelstein, A; Iaina, A; Koifman, B; Laniado, S; Peer, G; Scherez, J; Wollman, Y, 1995)
"We examined the effects of chronic oral L-arginine treatment on endothelial and cardiovascular function in rats with heart failure induced by coronary artery ligation."7.70Effects of L-arginine on endothelial and cardiac function in rats with heart failure. ( Arnold, JM; Arnold, O; Feng, Q; Fortin, AJ; Lu, X, 1999)
"enalapril alone to enhance vascular effects, increase LV contractility and prevent unfavorable remodeling and are consistent with vascular delivery of exogenous NO."5.32A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. ( Condorelli, G; Del Soldato, P; Dieterle, T; Gu, Y; Iwanaga, Y; Ongini, E; Peterson, KL; Presotto, C; Ross, J, 2004)
"Chronic heart failure is associated with increased levels of hypoxanthine and decreased levels of nitrite."5.11Home-based exercise training modulates pro-oxidant substrates in patients with chronic heart failure. ( Böger, R; Clark, AL; Coats, AJ; Niebauer, J; Webb-Peploe, KM, 2005)
"The aim of this study was to evaluate the hemodynamic effect of L-arginine infusion in patients with congestive heart failure."5.08Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. ( Blum, M; Bogomolny, N; Chernichowsky, T; Finkelstein, A; Iaina, A; Koifman, B; Laniado, S; Peer, G; Scherez, J; Wollman, Y, 1995)
" The inflammatory response expressed by PTX3 had a significant relationship with age, heart failure, infarct size, impaired flow in the infarct-related artery, and renal function and positively correlated with neopterin, TNF-α, 8-hydroxy-2'-deoxyguanosine, and nitrite/nitrate."3.81Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress. ( Ganovska, E; Gottwaldova, J; Jarkovsky, J; Kala, P; Kubena, P; Kubkova, L; Littnerova, S; Mebazaa, A; Mueller, C; Parenica, J; Pavkova Goldbergova, M; Poloczek, M; Spinar, J; Tomandl, J; Tomandlova, M, 2015)
"To examine the role of endothelin ETA and ETB receptors in congestive heart failure due to cardiomyopathy, the effect of chronic treatment with selective ETA- and ETB-receptor antagonists (atrasentan and A-192621, respectively), alone and in combination, was assessed on functional and biochemical parameters of 52-week-old Bio 14."3.74Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters. ( Bkaily, G; Carrier, E; D'Orleans-Juste, P; Fecteau, MH; Honoré, JC; Tirapelli, CR, 2008)
"We examined the effects of chronic oral L-arginine treatment on endothelial and cardiovascular function in rats with heart failure induced by coronary artery ligation."3.70Effects of L-arginine on endothelial and cardiac function in rats with heart failure. ( Arnold, JM; Arnold, O; Feng, Q; Fortin, AJ; Lu, X, 1999)
" The response of the resistance bed in the forearm after release of inflow occlusion (reactive hyperemia), to hand exercise, and to local heating and the response of the calf resistance vessels to arterial occlusion and intra-arterial sodium nitrite and phentolamine were studied in 23 patients with congestive heart failure and 21 normal subjects."3.64A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. ( Braunwald, E; Mason, DT; Zelis, R, 1968)
"There are few effective treatments for heart failure with preserved ejection fraction (HFpEF)."2.87Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. ( Anstrom, KJ; Borlaug, BA; Braunwald, E; Chen, HH; Davila-Roman, VG; Desvigne-Nickens, P; Felker, GM; Givertz, MM; Hernandez, AF; Koepp, GA; Levine, JA; LeWinter, MM; Lewis, GD; Mann, DL; Margulies, KB; McNulty, S; Redfield, MM; Shah, SJ; Smith, AL; Tang, WHW; Whellan, DJ, 2018)
"The efficacy of nitrite therapy for the treatment of heart failure remains controversial."2.82The Efficacy of Nitrite Therapy for the Treatment of Heart Failure: A Meta-Analysis of Randomized Controlled Trials. ( Xu, H; Zhang, Q; Zhou, Q, 2022)
"Cardiac arrest was induced by intravenous bolus of potassium chloride (40 µg/g)."2.78Sarcoplasmic phospholamban protein is involved in the mechanisms of postresuscitation myocardial dysfunction and the cardioprotective effect of nitrite during resuscitation. ( He, Q; Huang, Y; Yang, M; Zhan, L, 2013)
" A decrease in the production and bioavailability of NO is a hallmark of many major chronic diseases including hypertension, ischaemia-reperfusion injury, atherosclerosis and diabetes."2.53Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases. ( Lundberg, JO; Omar, SA; Webb, AJ; Weitzberg, E, 2016)
"enalapril alone to enhance vascular effects, increase LV contractility and prevent unfavorable remodeling and are consistent with vascular delivery of exogenous NO."1.32A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. ( Condorelli, G; Del Soldato, P; Dieterle, T; Gu, Y; Iwanaga, Y; Ongini, E; Peterson, KL; Presotto, C; Ross, J, 2004)
"Heart failure is associated with an increase in plasma nitrate and nitrite (NOx)."1.31Plasma nitrate accumulation during the development of pacing-induced dilated cardiac myopathy in conscious dogs is due to renal impairment. ( Hintze, TH; Laycock, S; Ochoa, M; Osorio, JC; Vogel, T; Xu, X, 2001)
" Long-term administration (2 mo) of the selective NOS II inhibitor S-methylisothiourea (SMT) to rats with MI significantly improved cardiac function."1.31Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. ( Fahas, L; Giaid, A; Hu, F; Saito, T; Shennib, H; Tayara, L, 2002)
"Heart failure is associated with an increase in plasma nitrate levels, and yet most experimental evidence demonstrates a reduction in endothelial nitric oxide production during heart failure."1.30Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs. ( Bernstein, RD; Forfia, P; Hintze, TH; Ochoa, F; Ochoa, M; Tuzman, J; Vogel, T; Zhang, X; Zhao, G, 1997)

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-199017 (23.94)18.7374
1990's10 (14.08)18.2507
2000's12 (16.90)29.6817
2010's24 (33.80)24.3611
2020's8 (11.27)2.80

Authors

AuthorsStudies
Namba, T1
Masaki, N1
Hitomi, Y1
Ishinoda, Y1
Iwashita, M1
Yumita, Y1
Kagami, K1
Yasuda, R1
Ikegami, Y1
Toya, T1
Nagatomo, Y1
Takase, B1
Soejima, K1
Adachi, T1
Zhou, Q2
Zhang, Q5
Xu, H3
Alogna, A1
Koepp, KE1
Sabbah, M1
Espindola Netto, JM1
Jensen, MD1
Kirkland, JL1
Lam, CSP1
Obokata, M1
Petrie, MC1
Ridker, PM1
Sorimachi, H1
Tchkonia, T1
Voors, A1
Redfield, MM2
Borlaug, BA2
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Wu, X2
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X8
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M3
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y2
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L4
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y4
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y3
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J1
Tian, J1
Zhao, M1
Hu, J2
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH1
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S3
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I2
Vogrin, S1
Neil, CJ2
Allen, JD3
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z3
Liang, H1
Xu, X2
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J3
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L1
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X2
Wang, D1
Hu, M1
Shen, H1
Yao, M1
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Woessner, MN1
McIlvenna, LC1
Neil, C1
Giam, B1
Nomura, H1
Kuruppu, S1
Chu, PY1
Essid, S1
Kiriazis, H1
Du, XJ1
Kaye, DM1
Rajapakse, NW1
Coggan, AR2
Racette, SB1
Thies, D2
Peterson, LR2
Stratford, RE1
Wan, SH1
Pandey, A1
Gee, LC1
Massimo, G1
Lau, C1
Primus, C1
Fernandes, D1
Rathod, KS1
Hamers, AJP1
Filomena, F1
Nuredini, G1
Ibrahim, AS1
Khambata, RS1
Gupta, AK1
Moon, JC1
Kapil, V1
Ahluwalia, A1
Shaltout, HA1
Eggebeen, J1
Marsh, AP1
Brubaker, PH1
Laurienti, PJ1
Burdette, JH1
Basu, S1
Morgan, A1
Dos Santos, PC1
Norris, JL1
Morgan, TM1
Miller, GD1
Rejeski, WJ1
Hawfield, AT1
Diz, DI1
Becton, JT1
Kim-Shapiro, DB1
Kitzman, DW1
Falls, R1
Seman, M1
Braat, S1
Sortino, J1
Broadstreet, SR1
Mahmood, K1
Mikhalkova, D1
Madigan, M1
Bole, I1
Leibowitz, JL1
Kadkhodayan, A1
Thomas, DP1
Polhemus, DJ1
Trivedi, RK1
Gao, J1
Scarborough, AL1
Goodchild, TT1
Varner, KJ1
Xia, H1
Smart, FW1
Kapusta, DR1
Lefer, DJ1
Chirinos, JA2
Anstrom, KJ1
Lewis, GD1
Shah, SJ1
Levine, JA1
Koepp, GA1
Givertz, MM1
Felker, GM1
LeWinter, MM1
Mann, DL1
Margulies, KB1
Smith, AL1
Tang, WHW1
Whellan, DJ1
Chen, HH1
Davila-Roman, VG1
McNulty, S1
Desvigne-Nickens, P1
Hernandez, AF1
Braunwald, E2
Wo, D1
Zhuang, P1
Xu, ZG1
Xu, S1
Mao, HM1
He, Q1
Zhan, L1
Bailey, JC1
Feelisch, M2
Horowitz, JD2
Frenneaux, MP3
Madhani, M3
Arif, S1
Borgognone, A1
Lin, EL1
O'Sullivan, AG1
Sharma, V1
Drury, NE1
Menon, A1
Nightingale, P1
Mascaro, J1
Bonser, RS1
Tomandlova, M2
Jarkovsky, J2
Tomandl, J2
Kubkova, L1
Kala, P2
Littnerova, S2
Gottwaldova, J2
Kubena, P1
Ganovska, E1
Poloczek, M1
Spinar, J2
Mueller, C1
Mebazaa, A2
Pavkova Goldbergova, M1
Parenica, J2
Omar, SA1
Webb, AJ1
Lundberg, JO2
Weitzberg, E1
Zamani, P1
Pavkova, MG1
Dastych, M1
Gayat, E1
Loudon, BL1
Noordali, H1
Gollop, ND1
Carlström, M1
Lai, YC1
Gladwin, MT1
Ryan, JJ1
Fang, JC1
Sharifi-Sanjani, M1
Tofovic, SP1
Honoré, JC1
Carrier, E1
Fecteau, MH1
Tirapelli, CR1
Bkaily, G1
D'Orleans-Juste, P1
Laurent, M1
Daline, T1
Malika, B1
Fawzi, O1
Philippe, V1
Benoit, D1
Catherine, M1
Jacques, R1
Doroszko, A1
Polewicz, D1
Cadete, VJ1
Sawicka, J1
Jones, M1
Szczesna-Cordary, D1
Cheung, PY1
Sawicki, G1
Heusch, P1
Aker, S1
Boengler, K1
Deindl, E1
van de Sand, A1
Klein, K1
Rassaf, T1
Konietzka, I1
Sewell, A1
Menazza, S1
Canton, M1
Heusch, G1
Di Lisa, F1
Schulz, R3
Bongartz, LG1
Joles, JA1
Verhaar, MC1
Cramer, MJ1
Goldschmeding, R1
Tilburgs, C1
Gaillard, CA1
Doevendans, PA1
Braam, B1
Kadiiska, MB1
Bonini, MG1
Ruggiero, C1
Cleland, E1
Wicks, S1
Stadler, K1
Sugamori, T1
Ishibashi, Y1
Shimada, T1
Takahashi, N1
Sakane, T1
Ohata, S1
Kunizawa, Y1
Inoue, S1
Nakamura, K1
Ohta, Y1
Shimizu, H1
Katoh, H1
Oyake, N1
Murakami, Y1
Hashimoto, M1
Sugahara, Y1
Ishii, M1
Muta, H1
Egami, K1
Akagi, T1
Matsuishi, T1
REAL, AP1
JOHNSON, JB2
GROSS, JF1
HALE, E1
BARNI, M1
RADO, JP1
GONDA, E1
KOVACS, E1
FAIRLEY, A1
CARTER, C1
SIMONI, Y1
HISATA, T1
RIU, T1
Iwanaga, Y1
Gu, Y1
Dieterle, T1
Presotto, C1
Del Soldato, P1
Peterson, KL1
Ongini, E1
Condorelli, G1
Ross, J1
HALMAGYI, D1
FELKAI, B1
HETENYI, G1
IVANYI, J1
SZEITZ, K1
Niebauer, J1
Clark, AL1
Webb-Peploe, KM1
Böger, R1
Coats, AJ1
Kirby, B1
Murashko, VV1
Iusipova, TA1
Strutynskiĭ, AV1
Dzhanashiia, PKh1
Sheshina, AM1
Dipalma, JR1
García Puig, J1
Gil Aguado, A1
Arnalich, F1
Gaspar, G1
Anciones, B1
Vázquez, JJ1
Koifman, B1
Wollman, Y1
Bogomolny, N1
Chernichowsky, T1
Finkelstein, A1
Peer, G1
Scherez, J1
Blum, M1
Laniado, S1
Iaina, A1
Seghaye, MC1
Duchateau, J1
Bruniaux, J1
Demontoux, S1
Détruit, H1
Bosson, C1
Lecronier, G1
Mokhfi, E1
Serraf, A1
Planché, C1
Kichuk, MR1
Oz, M1
Michler, R1
Kaley, G1
Nasjletti, A1
Hintze, TH3
Khadour, FH2
Kao, RH1
Armstrong, PW2
Holycross, BJ1
Bernstein, RD1
Zhao, G1
Forfia, P1
Tuzman, J1
Ochoa, F1
Ochoa, M2
Vogel, T2
Wang, WZ1
Matsumori, A1
Matoba, Y1
Matsui, S1
Sato, Y1
Hirozane, T1
Shioi, T1
Sasayama, S1
Preiser, JC1
De Backer, D1
Debelle, F1
Vray, B1
Vincent, JL1
Carville, C1
Adnot, S1
Sediame, S1
Benacerraf, S1
Castaigne, A1
Calvo, F1
de Cremou, P1
Dubois-Randé, JL1
O'Brien, DW1
Fu, Y1
Feng, Q1
Fortin, AJ1
Arnold, JM1
Arnold, O1
Lovell, SL1
Stevenson, H1
Young, IS1
McDowell, G1
McEneaney, D1
Riley, MS1
Nicholls, DP1
Prior, DL1
Chin-Dusting, JP1
Osorio, JC1
Laycock, S1
Eriksson, AS1
Järvinen, AK1
Eklund, KK1
Vuolteenaho, OJ1
Toivari, MH1
Nieminen, MS1
Chowdhary, S1
Ng, GA1
Nuttall, SL1
Coote, JH1
Ross, HF1
Townend, JN1
Saito, T1
Hu, F1
Tayara, L1
Fahas, L1
Shennib, H1
Giaid, A1
Pascal, N1
Rothlin, ME1
Zelis, R2
Nager, F1
Mason, DT1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Relaxation Breathing Exercises on Cardiovascular Parameters Among Hypertensive Patients[NCT06131528]40 participants (Anticipated)Interventional2023-10-30Recruiting
Acute Effects of Beetroot Juice on Locomotor Economy and Capacity in Chronic Stroke[NCT05720013]25 participants (Anticipated)Interventional2023-02-01Recruiting
Dietary Nitrate and Muscle Power With Aging[NCT03513302]20 participants (Actual)Interventional2019-03-01Completed
Dose-response Effect of Dietary Nitrate on Muscle Function in Older Individuals[NCT03595774]Phase 113 participants (Actual)Interventional2018-09-01Completed
Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF[NCT02742129]Phase 2105 participants (Actual)Interventional2016-08-10Completed
The Effect of NO Precursors on Physiological Responses to Exercise[NCT02850367]63 participants (Actual)Interventional2016-05-09Completed
Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial[NCT05450328]Phase 2141 participants (Anticipated)Interventional2022-09-01Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Average Arbitrary Accelerometer Units (AAU)

Average arbitrary accelerometer units (AAU) during at least 14 days and up to 21 days of the maximally tolerated dose of study drug (from 28 days post Study Visit 1 until Study Visit 2 and from 28 days post Study Visit 2 until Study Visit 3). An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based upon patient movement. Higher values indicate more movement. Zero indicates no movement. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionaccelerometry units (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo56925688
Placebo Crossover to AIR00153415289

Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Score

To evaluate whether AR001 improves quality of life in comparison to placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life). Higher values of the overall KCCQ score are considered to be better than lower values. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionunits on a scale (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo65.664.1
Placebo Crossover to AIR00159.859.4

Left Atrial Volume Index as Measured by Echocardiography

To evaluate whether AIR001 improves Left atrial volume index in comparison to placebo. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionml/m^2 (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo36.337.2
Placebo Crossover to AIR00140.139.1

Medial E/e' Ratio as Measured by Echocardiography Core Lab

To evaluate whether AIR001 improves Medial E/e' ratio (the ratio between early mitral inflow velocity and mitral annular early diastolic velocity for diastolic evaluation) in comparison to placebo. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionratio (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo15.415.0
Placebo Crossover to AIR00118.317.4

N-terminal Pro-B-type Natriuretic Peptide Level (NT-proBNP)

Evaluate whether AIR001 improves natriuretic peptide levels in comparison to placebo (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionpg/mL (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo494.8513.9
Placebo Crossover to AIR001550.4545.2

Patient Preference for AIR001 Treatment at the End of Study

Self-reported participant preference for study period 1 (Phase 1) vs. study period 2 (Phase 2) (NCT02742129)
Timeframe: End of Phase 2

,
InterventionParticipants (Count of Participants)
Phase 1 Patient Felt BetterPhase 2 Patient Felt BetterNo Preference
AIR001 Crossover to Placebo23178
Placebo Crossover to AIR001152012

Peak VO2

The primary endpoint will be the peak VO2 after 4 weeks treatment with inorganic nitrite as compared to the peak VO2 after 4 weeks treatment with placebo as assessed by cardiopulmonary exercise testing (CPET) performed at peak drug levels. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionml/kg/min (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo13.413.7
Placebo Crossover to AIR00113.813.6

Pulmonary Artery Systolic Pressure as Measured by Echocardiography

To evaluate whether AIR001 improves pulmonary artery systolic pressure in comparison to placebo. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
InterventionmmHg (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo38.235.0
Placebo Crossover to AIR00139.637.3

VE/VCO2 Slope (Ventilatory Efficiency) as Provided by Cardiopulmonary Exercise Testing Core Lab

To evaluate whether ARI001 in comparison to placebo improves ventilator efficiency as measured by Slope of Ve/VCO2 during study drug administration. The Ve/VCO2 slope is defined as the slope of the linear relationship between ventilation and carbon dioxide output and is a measure of the velocity. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionunitless (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo31.832.1
Placebo Crossover to AIR00133.933.6

VO2 at Ventilatory Threshold (Submaximal Exercise Capacity) as Provided by Cardiopulmonary Exercise Testing Core Lab

To evaluate whether ARI001 in comparison to placebo improves submaximal exercise capacity as measured by VO2 (rate of oxygen consumption measured during incremental exercise) at ventilatory threshold during study drug administration. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

,
Interventionml/min (Mean)
Phase 1Phase 2
AIR001 Crossover to Placebo7.87.9
Placebo Crossover to AIR0018.07.8

NYHA (New York Heart Association) Class

To evaluate whether AR001 improves NYHA Class in comparison to placebo. NYHA class was measured at the end of each phase. The site physician evaluated the patient based upon the criteria for NYHA class I-IV used by the American Heart Association. NYHA functional classification provides a way of classifying the extent of heart failure. Class I (least severe): No limitation of physical activity; Class II: Slight limitation of physical activity; Class III: Marked limitation of physical activity; Class IV (most severe): Unable to carry on any physical activity without discomfort. (NCT02742129)
Timeframe: End of Phase 1 & End of Phase 2

InterventionParticipants (Count of Participants)
Phase 172157333Phase 172157332Phase 272157333Phase 272157332
IIIIIIIV
AIR001 Crossover to Placebo1
AIR001 Crossover to Placebo21
Placebo Crossover to AIR00129
AIR001 Crossover to Placebo26
Placebo Crossover to AIR00120
AIR001 Crossover to Placebo0
Placebo Crossover to AIR0011
Placebo Crossover to AIR00122
AIR001 Crossover to Placebo24
Placebo Crossover to AIR00125
Placebo Crossover to AIR0010

Reviews

7 reviews available for nitrites and Heart Failure

ArticleYear
The Efficacy of Nitrite Therapy for the Treatment of Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
    The heart surgery forum, 2022, Oct-31, Volume: 25, Issue:5

    Topics: Blood Pressure; Heart Failure; Humans; Nitrites; Randomized Controlled Trials as Topic; Sexually Tra

2022
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Pharmacology and therapeutic role of inorganic nitrite and nitrate in vasodilatation.
    Pharmacology & therapeutics, 2014, Volume: 144, Issue:3

    Topics: Acute Disease; Animals; Diet; Heart Failure; Humans; Nitrates; Nitric Oxide; Nitrites; Phytochemical

2014
Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases.
    Journal of internal medicine, 2016, Volume: 279, Issue:4

    Topics: Animals; Biological Availability; Blood Pressure; Cardiovascular Diseases; Cardiovascular System; Di

2016
The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction.
    Current heart failure reports, 2016, Volume: 13, Issue:1

    Topics: Exercise Tolerance; Heart Failure; Hemodynamics; Humans; Metabolic Networks and Pathways; Nitrates;

2016
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm.
    British journal of pharmacology, 2016, Volume: 173, Issue:12

    Topics: Cardiovascular Agents; Heart Failure; Humans; Nitrites; Perhexiline

2016
Drug therapy for hypertension and ischemic heart disease.
    International anesthesiology clinics, 1980,Winter, Volume: 18, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Antihypertensive Agents; Arrhythmias, Cardiac; Cardiac Glycosides;

1980

Trials

12 trials available for nitrites and Heart Failure

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
The Effect of Dietary Inorganic Nitrate Supplementation on Cardiac Function during Submaximal Exercise in Men with Heart Failure with Reduced Ejection Fraction (HFrEF): A Pilot Study.
    Nutrients, 2020, Jul-17, Volume: 12, Issue:7

    Topics: Blood Pressure; Cross-Over Studies; Diet; Dietary Supplements; Double-Blind Method; Echocardiography

2020
Simultaneous Pharmacokinetic Analysis of Nitrate and its Reduced Metabolite, Nitrite, Following Ingestion of Inorganic Nitrate in a Mixed Patient Population.
    Pharmaceutical research, 2020, Nov-02, Volume: 37, Issue:12

    Topics: Administration, Oral; Aged; Aging; Biological Availability; Body Weight; Cross-Over Studies; Dietary

2020
Inorganic nitrate as a treatment for acute heart failure: a protocol for a single center, randomized, double-blind, placebo-controlled pilot and feasibility study.
    Journal of translational medicine, 2017, 08-08, Volume: 15, Issue:1

    Topics: Acute Disease; Double-Blind Method; Feasibility Studies; Heart Failure; Humans; Nitrates; Nitric Oxi

2017
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Dietary Nitrate Increases VO
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Cross-Over Studies; Dietary Supplements; Double-Blind Method; Exercise Tolerance; Female; Follow-Up

2018
Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial.
    JAMA, 2018, 11-06, Volume: 320, Issue:17

    Topics: Administration, Inhalation; Aged; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise T

2018
Sarcoplasmic phospholamban protein is involved in the mechanisms of postresuscitation myocardial dysfunction and the cardioprotective effect of nitrite during resuscitation.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Animals; Calcium-Binding Proteins; Heart; Heart Arrest; Heart Failure; Hemodynamics; Male; Myocardiu

2013
Training-induced increase in nitric oxide metabolites in chronic heart failure and coronary artery disease: an extra benefit of water-based exercises?
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:2

    Topics: Bicycling; Biomarkers; Catecholamines; Chronic Disease; Coronary Artery Disease; Exercise Therapy; E

2009
Home-based exercise training modulates pro-oxidant substrates in patients with chronic heart failure.
    European journal of heart failure, 2005, Mar-02, Volume: 7, Issue:2

    Topics: Adult; Arginine; Cross-Over Studies; Exercise; Female; Heart Failure; Humans; Hypoxanthine; Male; Mi

2005
Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure.
    Journal of the American College of Cardiology, 1995, Nov-01, Volume: 26, Issue:5

    Topics: Aged; Arginine; Coronary Disease; Female; Heart Failure; Hemodynamics; Humans; Injections, Intraveno

1995
Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure.
    Journal of cardiovascular pharmacology, 1998, Volume: 32, Issue:4

    Topics: Acetylcholine; Enzyme Inhibitors; Female; Forearm; Heart Failure; Hemodynamics; Humans; Male; Middle

1998
Transient improvement of acetylcholine responses after short-term oral L-arginine in forearms of human heart failure.
    Journal of cardiovascular pharmacology, 2000, Volume: 36, Issue:1

    Topics: Acetylcholine; Administration, Oral; Adult; Analysis of Variance; Arginine; Blood Pressure; Cross-Ov

2000

Other Studies

53 other studies available for nitrites and Heart Failure

ArticleYear
Association of serum nitric oxide metabolite level with mortality in patients undergoing coronary angiography.
    Journal of cardiology, 2022, Volume: 80, Issue:6

    Topics: Aged; Biomarkers; C-Reactive Protein; Coronary Angiography; Heart Failure; Humans; Middle Aged; Natr

2022
Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction.
    JACC. Heart failure, 2023, Volume: 11, Issue:11

    Topics: Exercise Tolerance; Heart; Heart Failure; Humans; Interleukin-6; Nitrites; Stroke Volume

2023
Endothelial-specific overexpression of cationic amino acid transporter-1 prevents loss of kidney function in heart failure.
    Clinical science (London, England : 1979), 2020, 10-30, Volume: 134, Issue:20

    Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathy, Dilated; Cationic Amino Acid Transporter 1; En

2020
Targeting the nitrate-nitrite-nitric oxide pathway in heart failure with preserved ejection fraction: too soon to say no to nitric oxide?
    European journal of heart failure, 2021, Volume: 23, Issue:5

    Topics: Heart Failure; Humans; Nitrates; Nitric Oxide; Nitrites; Stroke Volume

2021
Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide.
    British journal of pharmacology, 2022, Volume: 179, Issue:20

    Topics: Animals; Cardiomegaly; Case-Control Studies; Clinical Studies as Topic; Disease Models, Animal; Fibr

2022
Effects of supervised exercise and dietary nitrate in older adults with controlled hypertension and/or heart failure with preserved ejection fraction.
    Nitric oxide : biology and chemistry, 2017, Sep-30, Volume: 69

    Topics: Aged; Beta vulgaris; Blood Pressure; Dietary Supplements; Exercise; Female; Fruit and Vegetable Juic

2017
Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.
    Journal of the American College of Cardiology, 2017, Oct-24, Volume: 70, Issue:17

    Topics: Aminobutyrates; Angiotensin II; Animals; Biphenyl Compounds; Bisoprolol; Blood Pressure; Drug Combin

2017
The Nitrate-Nitrite-NO Pathway as a Novel Therapeutic Target in Heart Failure with Reduced Ejection Fraction.
    Journal of cardiac failure, 2018, Volume: 24, Issue:2

    Topics: Heart Failure; Humans; Nitrates; Nitrites; Stroke Volume; Ventricular Dysfunction, Left

2018
A novel spectrophotometric method for indirect determination of nitric oxide (NO) in serum.
    Clinica chimica acta; international journal of clinical chemistry, 2013, Sep-23, Volume: 424

    Topics: Adult; Aged; Cadmium; Case-Control Studies; Copper; Edetic Acid; Female; Heart Failure; Humans; Male

2013
Role of aldehyde dehydrogenase in hypoxic vasodilator effects of nitrite in rats and humans.
    British journal of pharmacology, 2015, Volume: 172, Issue:13

    Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Aldehydes; Animals; Arteries; C

2015
Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress.
    Disease markers, 2015, Volume: 2015

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Biomarkers; C-Reactive Protein; Deoxyguanosine; Female; Heart Fai

2015
Natriuretic peptides, nitrite/nitrate and superoxide dismutase have additional value on top of the GRACE score in prediction of one-year mortality and rehospitalisation for heart failure in STEMI patients - Multiple biomarkers prospective cohort study.
    International journal of cardiology, 2016, May-15, Volume: 211

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Female; Follow-Up Studies; Heart Failure

2016
Letter by Carlström and Lundberg Regarding Article, "SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction".
    Circulation, 2016, Aug-09, Volume: 134, Issue:6

    Topics: AMP-Activated Protein Kinases; Heart Failure; Humans; Hyperglycemia; Hypertension, Pulmonary; Metfor

2016
Response by Lai and Gladwin to Letter Regarding Article, "SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction".
    Circulation, 2016, Aug-09, Volume: 134, Issue:6

    Topics: AMP-Activated Protein Kinases; Heart Failure; Humans; Hyperglycemia; Hypertension, Pulmonary; Metfor

2016
Taking NO for an Answer: Exploring the Therapeutic Potential of Nitrite in HFpEF.
    Circulation research, 2016, 09-16, Volume: 119, Issue:7

    Topics: Heart Failure; Humans; Hypertension, Pulmonary; Nitrites; Stroke Volume

2016
Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding.
    Journal of cardiovascular pharmacology, 2017, Volume: 69, Issue:2

    Topics: Animals; Cells, Cultured; Heart Failure; Male; Mice; Mice, Inbred C57BL; Nitrites; Pulmonary Artery;

2017
Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters.
    Canadian journal of physiology and pharmacology, 2008, Volume: 86, Issue:6

    Topics: Animals; Atrasentan; Blood Pressure; Cardiomyopathies; Cricetinae; Endothelin A Receptor Antagonists

2008
Neonatal asphyxia induces the nitration of cardiac myosin light chain 2 that is associated with cardiac systolic dysfunction.
    Shock (Augusta, Ga.), 2010, Volume: 34, Issue:6

    Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Blotting, Western; Cardiac Myosins; Electrophoresis,

2010
Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation.
    American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:2

    Topics: Animals; Arginase; Arginine; Blotting, Western; Cardiac Pacing, Artificial; Disease Models, Animal;

2010
Subtotal nephrectomy plus coronary ligation leads to more pronounced damage in both organs than either nephrectomy or coronary ligation.
    American journal of physiology. Heart and circulatory physiology, 2012, Feb-01, Volume: 302, Issue:3

    Topics: Animals; Blood Pressure; Cardio-Renal Syndrome; Coronary Stenosis; Disease Models, Animal; Gene Expr

2012
Thiazolidinedione treatment decreases oxidative stress in spontaneously hypertensive heart failure rats through attenuation of inducible nitric oxide synthase-mediated lipid radical formation.
    Diabetes, 2012, Volume: 61, Issue:3

    Topics: Aldehydes; Animals; Body Composition; Free Radicals; Glucose Intolerance; Heart Failure; Hypertensio

2012
Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cardiomyopathy: close correlation of tumor necrosis factor-alpha with systemic and local production of nitric oxide.
    Circulation journal : official journal of the Japanese Circulation Society, 2002, Volume: 66, Issue:7

    Topics: Adult; Aged; Arm; Cardiomyopathy, Dilated; Case-Control Studies; Female; Heart Failure; Heart Functi

2002
Efficacy and safety of thermal vasodilation therapy by sauna in infants with severe congestive heart failure secondary to ventricular septal defect.
    The American journal of cardiology, 2003, Jul-01, Volume: 92, Issue:1

    Topics: Echocardiography, Doppler, Color; Female; Heart Failure; Heart Septal Defects, Ventricular; Hemodyna

2003
[Nebulization of trinitrin in dyspneic episodes of left cardiac insufficiency].
    La Semana medica, 1956, Jan-05, Volume: 108, Issue:1

    Topics: Dyspnea; Heart Failure; Humans; Nitrites; Nitroglycerin

1956
Effects of sublingual administration of nitroglycerin on pulmonary-artery pressure in patients with failure of the left ventricle.
    The New England journal of medicine, 1957, Dec-05, Volume: 257, Issue:23

    Topics: Administration, Sublingual; Arteries; Blood Pressure; Blood Pressure Determination; Heart Failure; H

1957
[Fatal crises in acute coronary insufficiency caused by chronic poisoning by nitrolycol].
    Atti della Accademia dei fisiocritici in Siena. Sezione medico-fisica, 1957, Volume: 4

    Topics: Angina, Unstable; Chronic Disease; Heart Failure; Humans; Nitrites

1957
The role of venous constriction in circulatory disorders.
    British heart journal, 1958, Volume: 20, Issue:3

    Topics: Cardiovascular Diseases; Constriction; Constriction, Pathologic; Heart Failure; Nitrites; Vascular D

1958
Effects of sublingual nitroglycerin on pulmonary arterial pressure in patients with left ventricular failure.
    Annals of internal medicine, 1959, Volume: 50, Issue:1

    Topics: Arterial Pressure; Heart Failure; Humans; Hypertension; Nitrites; Nitroglycerin

1959
Conditioned reflex reproduction of the effects of novurit (mercurial diuretic) and nitroglycerin in patients with cardiac decompensation, hypertension and coronary insufficiency.
    Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 1961, Volume: 11

    Topics: Alkylmercury Compounds; Conditioning, Classical; Coronary Disease; Diuretics; Drug Combinations; Hea

1961
[CLINICAL TRIAL OF THE CORONARY CIRCULATION-STIMULATING DRUG ETAMIN].
    [Chiryo] [Therapy], 1964, Volume: 46

    Topics: Arteriosclerosis; Coronary Circulation; Coronary Disease; Gastritis; Geriatrics; Heart Failure; Hype

1964
A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Cardiomyopathy, Dilated; Cricetinae; Cytos

2004
[Effect of sodium nitrite in acute cardiac insufficiency].
    Magyar belorvosi archivum es ideggyogyaszati szemle, 1951, Volume: 4, Issue:2

    Topics: Cardiovascular Diseases; Heart; Heart Failure; Humans; Nitrites; Sodium Nitrite

1951
[Effect of sodium nitrite on blood rheology, microcirculation and blood coagulability in patients with circulatory failure].
    Terapevticheskii arkhiv, 1984, Volume: 56, Issue:4

    Topics: Adult; Aged; Blood Coagulation; Blood Viscosity; Conjunctiva; Drug Evaluation; Drug Therapy, Combina

1984
The nitrites and nitrates.
    American family physician, 1982, Volume: 25, Issue:2

    Topics: Angina Pectoris; Angina Pectoris, Variant; Drug Interactions; Ethanol; Heart Failure; Liver; Mouth F

1982
[Treatment of cardiac insufficiency with systemic vasodilator agents].
    Medicina clinica, 1980, Nov-25, Volume: 75, Issue:9

    Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Nitrites; Nitroprusside; Prazosin; Vasodilator Age

1980
Endogenous nitric oxide production and atrial natriuretic peptide biological activity in infants undergoing cardiac operations.
    Critical care medicine, 1997, Volume: 25, Issue:6

    Topics: Atrial Natriuretic Factor; Blood Pressure; Cardiopulmonary Bypass; Cyclic GMP; Heart Failure; Heart

1997
Angiotensin-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts.
    The American journal of cardiology, 1997, Aug-04, Volume: 80, Issue:3A

    Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Child; Child, Preschool; Coronary Vesse

1997
Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure.
    The American journal of physiology, 1997, Volume: 273, Issue:3 Pt 2

    Topics: Aging; Animals; Endothelium, Vascular; Heart; Heart Failure; Heart Ventricles; Male; Nitrates; Nitri

1997
Mechanisms of nitrate accumulation in plasma during pacing-induced heart failure in conscious dogs.
    Nitric oxide : biology and chemistry, 1997, Volume: 1, Issue:5

    Topics: Acetylcholine; Animals; Blood Pressure; Bradykinin; Carbon Dioxide; Cardiac Pacing, Artificial; Coro

1997
Protective effects of Mu-Fang-Ji-Tang against myocardial injury in a murine model of congestive heart failure induced by viral myocarditis.
    Life sciences, 1998, Volume: 62, Issue:13

    Topics: Animals; Body Weight; Cell Line; Disease Models, Animal; Drugs, Chinese Herbal; Heart Failure; Macro

1998
The metabolic fate of long-term inhaled nitric oxide.
    Journal of critical care, 1998, Volume: 13, Issue:3

    Topics: Administration, Inhalation; Adult; Aged; Cardiac Surgical Procedures; Drug Monitoring; Female; Heart

1998
Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure.
    The American journal of physiology, 1998, Volume: 275, Issue:6

    Topics: Animals; Blotting, Western; Cardiac Pacing, Artificial; Creatinine; Densitometry; Dogs; Heart Atria;

1998
Effects of L-arginine on endothelial and cardiac function in rats with heart failure.
    European journal of pharmacology, 1999, Jul-02, Volume: 376, Issue:1-2

    Topics: Animals; Aorta, Thoracic; Arginine; Endothelium, Vascular; Heart; Heart Failure; Hemodynamics; Male;

1999
Exhaled nitric oxide during incremental and constant workload exercise in chronic cardiac failure.
    European journal of clinical investigation, 2000, Volume: 30, Issue:3

    Topics: Aged; Exercise; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Nitrate

2000
Plasma nitrate accumulation during the development of pacing-induced dilated cardiac myopathy in conscious dogs is due to renal impairment.
    Nitric oxide : biology and chemistry, 2001, Volume: 5, Issue:1

    Topics: Animals; Ascites; Cachexia; Cardiac Pacing, Artificial; Cardiomyopathy, Dilated; Consciousness; Crea

2001
Effect of age and body weight on neurohumoral variables in healthy Cavalier King Charles spaniels.
    American journal of veterinary research, 2001, Volume: 62, Issue:11

    Topics: Age Factors; Animals; Atrial Natriuretic Factor; Body Weight; Cardiac Output; Creatinine; Cyclic GMP

2001
Nitric oxide and cardiac parasympathetic control in human heart failure.
    Clinical science (London, England : 1979), 2002, Volume: 102, Issue:4

    Topics: Adult; Aged; Baroreflex; Blood Pressure; Cardiotonic Agents; Cross-Over Studies; Enzyme Inhibitors;

2002
Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure.
    American journal of physiology. Heart and circulatory physiology, 2002, Volume: 283, Issue:1

    Topics: Animals; Blotting, Western; Coronary Vessels; Disease Models, Animal; Enzyme Inhibitors; Heart Failu

2002
Letter: Cardiac failure.
    British medical journal, 1976, Aug-28, Volume: 2, Issue:6034

    Topics: Heart Failure; Humans; Isosorbide Dinitrate; Nitrites; Nitroglycerin

1976
[Current management of left heart failure].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1987, Dec-01, Volume: 76, Issue:49

    Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Catecholamines; Digitalis Glycoside

1987
The contribution of local factors to the elevated venous tone of congestive heart failure.
    The Journal of clinical investigation, 1974, Volume: 54, Issue:2

    Topics: Adult; Blood Pressure; Blood Volume; Constriction; Ethacrynic Acid; Heart Failure; Humans; Injection

1974
[Conservative therapy of angina pectoris].
    Schweizerische medizinische Wochenschrift, 1970, May-16, Volume: 100, Issue:20

    Topics: Acute Disease; Amyl Nitrite; Angina Pectoris; Anticoagulants; Coronary Disease; Digitalis Glycosides

1970
A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure.
    The Journal of clinical investigation, 1968, Volume: 47, Issue:4

    Topics: Adult; Forearm; Heart Failure; Hot Temperature; Humans; Hyperemia; Leg; Middle Aged; Nitrites; Phent

1968